[go: up one dir, main page]

MX2021013220A - Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion. - Google Patents

Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion.

Info

Publication number
MX2021013220A
MX2021013220A MX2021013220A MX2021013220A MX2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A
Authority
MX
Mexico
Prior art keywords
methods
reduce
composition obtained
enzymatic hydrolysis
activity rate
Prior art date
Application number
MX2021013220A
Other languages
English (en)
Inventor
Michael Leiss
Christian Meyer
Alexandra Thomas Morris
Bernhard Spensberger
Yinges Yigzaw
Franziska Edelmann
Roberto Falkenstein
Tobias Graf
Jie Gu
Jeevan Prabhakar
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2021013220A publication Critical patent/MX2021013220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
    • B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
    • B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/20—Other self-supporting filtering material ; Other filtering material of inorganic material, e.g. asbestos paper, metallic filtering material of non-woven wires
    • B01D39/2068—Other inorganic materials, e.g. ceramics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
    • B01D2239/06—Filter cloth, e.g. knitted, woven non-woven; self-supported material
    • B01D2239/0604—Arrangement of the fibres in the filtering material
    • B01D2239/0618—Non-woven
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/147—Microfiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Geology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona plataformas de purificación que comprenden una etapa de filtro de profundidad y/o una etapa de cromatografía de interacción hidrófoba (HIC). En la presente también se divulgan métodos para usar las plataformas de purificación descritas en la presente y composiciones obtenidas a partir de estas, tales como composiciones farmacéuticas.
MX2021013220A 2019-05-03 2020-05-01 Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion. MX2021013220A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843261P 2019-05-03 2019-05-03
US202062961609P 2020-01-15 2020-01-15
PCT/US2020/031164 WO2020227144A1 (en) 2019-05-03 2020-05-01 Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform

Publications (1)

Publication Number Publication Date
MX2021013220A true MX2021013220A (es) 2021-12-10

Family

ID=70779952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013220A MX2021013220A (es) 2019-05-03 2020-05-01 Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion.

Country Status (13)

Country Link
US (1) US12479883B2 (es)
EP (1) EP3962924A1 (es)
JP (2) JP2022531317A (es)
KR (2) KR20250057918A (es)
CN (1) CN114981286B (es)
AU (2) AU2020268896B2 (es)
BR (1) BR112021021972A2 (es)
CA (1) CA3137116A1 (es)
IL (1) IL287689A (es)
MX (1) MX2021013220A (es)
SG (1) SG11202111938YA (es)
TW (1) TWI870403B (es)
WO (1) WO2020227144A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3962924A1 (en) 2019-05-03 2022-03-09 Genentech, Inc. Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
EP4204816A1 (en) * 2020-08-31 2023-07-05 Genentech, Inc. High throughput, fluorescence-based esterase activity assay for assessing polysorbate degradation risk during biopharmaceutical development
KR20230098589A (ko) * 2020-10-30 2023-07-04 제넨테크, 인크. 감소된 가수분해 효소 활성률을 갖는 약제학적 조성물을 수득하기 위한 정제 플랫폼

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
CA1254945A (en) 1986-02-27 1989-05-30 Marco F. Cardosi Application of tetrathiafulvalenes in bioelectrochemical processes
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
ATE555666T1 (de) * 2002-05-23 2012-05-15 Ortho Clinical Diagnostics Inc Einfang, konzentration und quantifizierung eines abnormalen prionproteins aus biologischen flüssigkeiten mittels tiefenfiltration
US7645312B2 (en) * 2004-10-15 2010-01-12 3M Innovative Properties Company Pleated multi-layer filter media and cartridge
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
DE102008037678A1 (de) 2008-08-14 2010-02-25 Sartorius Stedim Biotech Gmbh Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid
WO2010048192A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
CN107365346A (zh) 2010-05-25 2017-11-21 弗·哈夫曼-拉罗切有限公司 纯化多肽的方法
CA2803228C (en) 2010-07-08 2019-03-12 Devirex Ag Polyethylene glycol compositions for controlling relapse of herpes labialis, herpes genitalis, and herpes zoster
EP2697369B1 (en) 2011-03-25 2018-06-27 F.Hoffmann-La Roche Ag Novel protein purification methods
KR101949187B1 (ko) 2011-07-08 2019-04-22 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
TW201348247A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
WO2015023468A1 (en) 2013-08-15 2015-02-19 3M Innovative Properties Company Filter element and filtration assembly for biopharmaceutical applications
SG10202006161UA (en) 2013-08-30 2020-07-29 Emd Millipore Corp High capacity composite depth filter media with low extractables
US20160272674A1 (en) 2013-11-07 2016-09-22 Abbvie Inc. Isolation and purification of antibodies
AU2014352824B2 (en) * 2013-11-25 2019-07-18 Seagen Inc. Preparing antibodies from CHO cell cultures for conjugation
CN114702594B (zh) 2013-12-20 2025-05-09 豪夫迈·罗氏有限公司 双重特异性抗体
FR3018450B1 (fr) * 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
JP6744292B2 (ja) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
WO2016106291A1 (en) * 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
CN116063543A (zh) 2015-04-24 2023-05-05 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
SI4209499T1 (sl) 2015-08-13 2025-01-31 Amgen Inc. Globinsko nabito filtriranje proteinov, ki vežejo antigen
MX2018002068A (es) 2015-08-20 2018-06-06 Genentech Inc Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
GB201521238D0 (en) 2015-12-02 2016-01-13 Auspherix Ltd Anti-bacterial compounds
GB201521240D0 (en) 2015-12-02 2016-01-13 Auspherix Ltd Anti-bacterial compounds
ES3038408T3 (en) * 2015-12-30 2025-10-13 Hoffmann La Roche Formulations with reduced degradation of polysorbate
BR112018075516A2 (pt) * 2016-06-17 2019-10-01 Genentech, Inc. purificação de anticorpos multiespecíficos
HRP20250718T1 (hr) 2016-08-15 2025-08-15 F. Hoffmann-La Roche Ag Kromatografski postupak za kvantifikaciju neionskog surfaktanta u sastavu koji sadrži neionski surfaktant i polipeptid
WO2018170488A1 (en) 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
US11760777B2 (en) 2017-04-26 2023-09-19 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
PL3731872T3 (pl) 2017-12-29 2022-03-21 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
KR20200136464A (ko) 2018-03-29 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 단량체성 모노클로날 항체를 정제하는 방법
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
EP3826743A4 (en) 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. METHODS FOR SEPARATION OF HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC METHODS
TWI871300B (zh) 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
HU231498B1 (hu) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
EP3962924A1 (en) 2019-05-03 2022-03-09 Genentech, Inc. Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
TW202140511A (zh) 2020-01-15 2021-11-01 瑞士商赫孚孟拉羅股份公司 減少來自重組蛋白生產過程中的雜質之方法
EP4100866A1 (en) 2020-02-04 2022-12-14 F. Hoffmann-La Roche AG Automated assessment of endoscopic disease
KR20230098589A (ko) 2020-10-30 2023-07-04 제넨테크, 인크. 감소된 가수분해 효소 활성률을 갖는 약제학적 조성물을 수득하기 위한 정제 플랫폼

Also Published As

Publication number Publication date
CN114981286B (zh) 2026-02-13
CA3137116A1 (en) 2020-11-12
US20220194980A1 (en) 2022-06-23
KR20220002581A (ko) 2022-01-06
US12479883B2 (en) 2025-11-25
TW202532427A (zh) 2025-08-16
TWI870403B (zh) 2025-01-21
WO2020227144A1 (en) 2020-11-12
EP3962924A1 (en) 2022-03-09
JP2024062995A (ja) 2024-05-10
AU2020268896A8 (en) 2021-10-28
AU2020268896A1 (en) 2021-09-30
KR20250057918A (ko) 2025-04-29
BR112021021972A2 (pt) 2021-12-21
IL287689A (en) 2021-12-01
TW202108600A (zh) 2021-03-01
WO2020227144A8 (en) 2021-12-02
AU2020268896B2 (en) 2024-11-28
SG11202111938YA (en) 2021-11-29
CN114981286A (zh) 2022-08-30
JP2022531317A (ja) 2022-07-06
AU2025201439A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
CY1121877T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
DK2046820T3 (da) Muteiner af tåre-lipocalin og fremgangsmåder til opnåelse deraf
MX2021013220A (es) Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion.
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
AU2017319323A8 (en) Biaryl compounds useful as immunomodulators
WO2007075598A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
ATE553105T1 (de) Azetidin-analoge ais nucleosidase- und phosphorylase-hemmer
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
NO20064584L (no) Tetrahydropyridoindolderivater
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
HK1251566A1 (zh) 作为hdac1/2抑制剂的呱啶衍生物
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
WO2023122782A3 (en) Indoles, indazoles, and related analogs for inhibiting yap/taz-tead
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
MX2019009229A (es) Novedosas variantes enzimaticas que degradan la nicotina.